Since the approval of pertuzumab together with trastuzumab and chemotherapy for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer [1], followed by its incorporation into the early breast cancer (EBC) setting [2], much has evolved and is still unfolding. This evidence concerns the gene ERBB2 and breast cancer.